Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
225
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Comparison of high-dose, short-course levofloxacin treatment vs conventional regimen against acute bacterial infection: meta-analysis of randomized controlled trials

Chih-Wei Chen1 Division of Neurosurgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan;2 Department of Occupational Safety and Health, Institute of Industrial Safety and Disaster Prevention, College of Sustainable Environment, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
,
Yu-Hung Chen3 Department of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan
,
I-Ling Cheng3 Department of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan
&
Chih-Cheng Lai4 Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, TaiwanCorrespondence[email protected]
Pages 1353-1361 | Published online: 17 May 2019

References

  • Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68:535–565. doi:10.2165/00003495-200868040-0001118318569
  • Frei CR, Burgess DS. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy. 2005;25:1161–1167. doi:10.1592/phco.2005.25.9.116116164390
  • Zhanel GG, Fontaine S, Adam H, et al. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med. 2006;5:437–465.17154673
  • Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother. 2003;37:1478–1488. doi:10.1345/aph.1C41914519053
  • Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752–760. doi:10.1086/37753912955634
  • Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med. 2006;100:2129–2136. doi:10.1016/j.rmed.2006.03.01916730170
  • Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin Ther. 2005;27:1251–1259.16199249
  • Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004;20:555–563. doi:10.1185/03007990412500330415119993
  • Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23:2637–2645. doi:10.1185/030079907X23334017880755
  • Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71:17–22. doi:10.1016/j.urology.2007.09.00218242357
  • Poole M, Anon J, Paglia M, Xiang J, Khashab M, Kahn J. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg. 2006;134:10–17. doi:10.1016/j.otohns.2005.11.02616399173
  • Ren H, Li X, Ni ZH, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol. 2017;49:499–507. doi:10.1007/s11255-017-1507-028108978
  • Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d592822008217
  • Zhao T, Chen LA, Wang P, et al. A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia. J Thorac Dis. 2016;8:2473–2484. doi:10.21037/jtd.2016.08.3027746999
  • Zhao X, Wu JF, Xiu QY, et al. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia. Diagn Microbiol Infect Dis. 2014;80:141–147. doi:10.1016/j.diagmicrobio.2013.11.00825130297
  • Mospan GA, Wargo KA. 5-Day versus 10-day course of fluoroquinolones in outpatient males with a urinary tract infection (UTI). J Am Board Fam Med. 2016;29:654–662. doi:10.3122/jabfm.2016.06.16006528076247
  • File TM Jr, Milkovich G, Tennenberg AM, et al. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin. 2004;20:1473–1481. doi:10.1185/030079904X255615383197

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.